Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IRIDEXIRIX -0.89%49 3-Year EPS without NRI Growth Rate is 17.90% as of Jun. 2026, which is 61% above its 10-year median of 11.10. GuruFocus rates IRIX with a GF Score™ of 49/100 and a GF Value™ of $1.47 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 656 Medical Devices & Instruments companies, IRIDEX ranks better than 62.65% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 17.90% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 3.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of IRIDEX was 211.80% per year. The lowest was -197.30% per year. And the median was 11.10% per year.
IRIDEX (NAS:IRIX) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
IRIDEX 3-Year EPS without NRI Growth Rate Related Terms
IRIX vs NMTC, CSDX, MODD: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Devices subindustry, IRIDEX's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IRIDEX 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, IRIDEX's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where IRIDEX's 3-Year EPS without NRI Growth Rate falls into.
IRIDEX 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 17.90% mean?
IRIDEX (IRIX) has a 3-Year EPS without NRI Growth Rate of 17.90% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for IRIDEX and its competitors. This is 61% above median its historical median of 11.10. According to the industry distribution chart, IRIDEX ranks #245 out of 656 companies in the Medical Devices & Instruments industry, placing it in the top 37.3%.
Is IRIDEX's 3-Year EPS without NRI Growth Rate too high?
IRIDEX's current 3-Year EPS without NRI Growth Rate of 17.90% is 61% above median its 10-year median of 11.10. The Medical Devices & Instruments industry median 3-Year EPS without NRI Growth Rate is 8.05. IRIDEX's value of 17.90% is 122.4% above this industry median. Based on the distribution chart, IRIDEX ranks #245 out of 656 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, IRIDEX has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IRIDEX's 3-Year EPS without NRI Growth Rate compare to NMTC and CSDX?
According to the Medical Devices & Instruments industry distribution chart, IRIDEX ranks #245 out of 656 companies for 3-Year EPS without NRI Growth Rate. This puts IRIDEX in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 8.05. IRIDEX's value of 17.90% is 122.4% above this benchmark. While the company's 10-year median is 11.10 vs. the industry median of 8.05, IRIDEX has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 8.05, based on 656 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IRIDEX's current 3-Year EPS without NRI Growth Rate of 17.90% is 122.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for IRIDEX and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 8.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IRIDEX's current 3-Year EPS without NRI Growth Rate is 17.90%, which is 61% above median its own 10-year median of 11.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IRIDEX stock overvalued right now?
Based on GuruFocus' analysis, IRIDEX (IRIX) is currently considered Possible Value Trap. The stock's GF Value™ is $1.47, compared to a current price of $0.78 — trading 46.7% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 17.90%, which is 61% above median its 10-year median of 11.10 and 122.4% above the Medical Devices & Instruments industry median of 8.05. IRIDEX's overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For IRIDEX (IRIX), the current 3-Year EPS without NRI Growth Rate is 17.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IRIDEX (IRIX) Overvalued in 2026?
Based on GuruFocus' analysis, IRIDEX stock appears to be undervalued.
The current stock price of $0.78 is trading 46.7% below its estimated GF Value™ of $1.47.
GuruFocus considers IRIDEX to be Possible Value Trap.
Key valuation signals for IRIX:
3-Year EPS without NRI Growth Rate: 17.90% (61% above median its 10-year median of 11.10)
GF Value™: $1.47 vs. price of $0.78 (46.7% below fair value)
Industry Position: 122.4% above the Medical Devices & Instruments median (#245 of 656)
No single metric tells the full story. See the IRIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
49GF Score
Get the complete analysis for IRIX
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IRIX has been successfully added to your 
